PeS-9
PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C26H28O13S
- 分子量:580.56
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors[1].
体外実験
PeS-9 (48 h) shows cytotoxicity in cancer cells with IC50s of 0.49 μM (DU145), and 0.58 μM (LNCaP), while has low cytotoxicity for noncancer cells with IC50s of 3.41 μM (PNT2), 3.53 μM (MRC-9), 11.7 μM (HUVEC) and 7.51 μM (HEK)[1].
PeS-9 (0-2.5 μM, 4-48 h) downregulates the AR signaling pathway, produces ROS, and damages DNA in 22Rv1 cells[1].
PeS-9 (48 h) synergizes with antiandrogen Enzalutamide (HY-70002) and PARP inhibitor Olaparib (HY-10162) with CI < 0.75 in 22Rv1 cells[1].
PeS-9 (0-1 μM, 1 h) activates the MAPK signaling pathways by increasing the level of stress kinases p-p38, p-JNK, and p-ERK in 22Rv1 cells, which can be antagonized by the tested MAPK inhibitor[1].
PeS-9 (0-2.5 μM, 1-48 h) induces apoptosis in 22Rv1 cells through mitochondrial targeting and cytotoxic ROS induction[1].
PeS-9 (0-2.5 μM, 1-48 h) causes increased cytosolic Ca2+ levels, expansion of the endoplasmic reticulum (ER), altered mitochondrial membrane permeability, and DNA damage, as quantified by an elevated sub-G1 cell population[1].
PeS-9 (0.5-4 μM, 24 h) inhibits the uptake of glucose in 22Rv1 cells, and this effect can be inhibited by GLUT-1 inhibitor Phloretin (HY-N0142)[1].
PeS-9 (0.1-10 μM, every 5 days over 20 days) reduces the survival fractions of tumoroids upon dose-dependently[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:22Rv1 cells
-
Concentration:1, 2 μM
-
Incubation Time:48 h
-
Result:Downregulated AR-FL, AR-V7, PSA, IGF-1 proteins dose-dependently.
-
Cell Line:22Rv1 cells
-
Concentration:0, 0.5, 1, 2 μM
-
Incubation Time:48 h
-
Result:Inhibited the transcription of TMPRSS2, FKBP5 and PSA genes dose-dependently.
-
Cell Line:22Rv1 cells
-
Concentration:1.25, 2.5 μM
-
Incubation Time:4, 24 h,48h
-
Result:Induced DNA double-strand breaks (DSBs), as demonstrated by γH2AX/53BP1 foci formation Triggered primary DNA damage within 4 hours of treatment, reached peak damage levels at 24 hours, and showed signs of DNA repair activation by 48 hours.
-
Cell Line:22Rv1 cells
-
Concentration:0.5-4 μM
-
Incubation Time:48 h
-
Result:Increased Bax/Bcl-2 ratio (0.5, 1, 2, 4, 8 μM).
Downregulated of antiapoptotic surviving-survivin (1, 2 μM).
Released cytotoxic mitochondrial proteins such as apoptosis-inducing factor (AIF) and cytochrome C to cellular cytoplasm (2, 4 μM).
Increased the level of caspase-9, caspase-3 and PRAP (2, 4 μM).
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID gamma (NSG) 8-12 weeks mice bearing subcutaneously xenotransplanted human prostate cancer 22Rv1 cells[1].
-
Dosage:27.9 mg/kg
-
Administration:Daily i.p. administration for 15 days
-
Result:Reduced 40.0% tumor volume compared with the control group (1069.5 mm3 vs. 646.6 mm3).
Reduced 4.4-fold lung micrometastases.
Showed no significant difference on the weights of the body, heart, lungs, liver, and kidney.
Enlarged spleen that indicate an immunostimulatory effect of the treatment.
Showed no significant difference on the white and red blood cells, platelets, hemoglobin content, and hematocrit.
Revealed no signs of tissue damage, inflammation or granuloma.
化学情報
-
分子量 580.56
-
分子式 C26H28O13S
-
SMILES
COC1=C(CSC[C@H]2O[C@H]([C@@H]([C@H]([C@@H]2OC(C)=O)OC(C)=O)OC(C)=O)OC(C)=O)C(C3=C(C=CC=C3O)C1=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)